Technology News and Research

RSS

High levels of mercury in fish can cause adverse health effects

Mercury levels in a popular species of game fish in Lake Erie are increasing after two decades of steady decline, scientists are reporting. The study, the most comprehensive to date on mercury levels in Great Lakes fish, is in ACS' Environmental Science & Technology, a semi-monthly journal.

15 Jul 2010

MD Buyline identifies top emerging technologies with highest impact

This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.

15 Jul 2010

Two patents issued for GlycoMimetics lead drug candidate, related compounds

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.

15 Jul 2010

Biotage introduces ExploraSep 96-well screening plates to identify optimum scavengers

Biotage, a leading supplier of tools and technology for analytical and medicinal chemistry, announced the introduction of ExploraSep 96-well screening plates to identify optimum scavengers. The 4 different screening plates deliver 128 selective resins based on high-performance, Molecularly Imprinted Polymers (MIPs). Biotage provides professional MIPs technical consultation, information on additional formats as well as assistance with data interpretation and process development.

15 Jul 2010

IBM and Peking University People's Hospital build evidence-based patient centric care system

IBM and Peking University People's Hospital have built an evidence-based patient centric care (ePC3) system to enable cooperation and resource sharing among medical services providers for improved patient care.

15 Jul 2010

New myopia control technology for eye health benefits from Vision CRC

Scientists from the Vision Cooperative Research Centre in Australia have announced that myopia, or short-sightedness, can be controlled with new technology. This ground breaking discovery was based on research conducted by Vision CRC partners – the University of Houston College of Optometry and the Brien Holden Vision Institute, located at the University of New South Wales.

15 Jul 2010

$Osseon receives notice of allowance for spinal vertebral compression fracture technology$

Osseon receives notice of allowance for spinal vertebral compression fracture technology

Osseon Therapeutics, Inc., a biomedical device company based in Santa Rosa, California, today received a notice of allowance for its spinal vertebral compression fracture (VCF) technology. The company which was started in 2006 has thirteen additional patent applications pending in the United States and throughout the world for related spinal therapies and devices. The lead inventor for this inaugural patent is Dr. Y. King Liu, one of three founders of Osseon.

15 Jul 2010

Hospital for Special Surgery named top hospital for orthopedics

Hospital for Special Surgery has been named the top hospital in the nation for orthopedics by U.S. News & World Report in its 2010 "America's Best Hospitals" issue. Once again the hospital ranked as a leader in rheumatology at number 3 in the nation. In addition, neurology was ranked at number 16.

15 Jul 2010

NIH awards $38.2M grant to Georgetown-Howard Universities Center for Clinical and Translational Science

In support of a critical partnership between Georgetown University Medical Center and Howard University, the National Institutes of Health (NIH) has awarded a $38.2 million Clinical and Translational Sciences Award to aid the universities' effort to transform health care and preventive practices in communities through medical discoveries made in laboratories and clinical settings.

15 Jul 2010

CardioGenics Holdings' subsidiary signs second product agreement with Merck Chimie

CardioGenics Holdings Inc., developer of the ultra-sensitive QL Care Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that the Company's subsidiary, CardioGenics Inc., has entered into an agreement with Merck Chimie S.A.S. to adopt its proprietary biological-linking technology to Merck-supplied magnetic beads designed to increase yields in antibody manufacturing.

15 Jul 2010

Final rules for e-health rewards unveiled

The federal government has issued new regulations defining the "meaningful use" of electronic medical records, a requirement doctors must fulfill in order to gain funds from a $27-billion pot set aside in the 2009 stimulus law, The New York Times reports. "A doctor can receive up to $44,000 under Medicare and $63,750 under Medicaid, while a hospital can receive millions of dollars, depending on its size."

15 Jul 2010

Tepha receives $3.2 million credit facility from GE Capital

GE Capital, Healthcare Financial Services today announced it has provided a $3.2 million credit facility to Tepha, Inc. The financing provides Tepha with working capital as it expands global commercialization efforts.

15 Jul 2010

Aestus, Eisai collaborate to research and develop novel therapeutics for psychiatric disorders

Aestus Therapeutics, Inc. announced today a collaboration agreement with Eisai Inc. on research and development of novel therapeutics for the treatment of psychiatric disorders. The multi-year collaboration will entail pre-clinical validation of potential therapeutics leading to clinical proof-of-concept studies.

15 Jul 2010

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Amorfix Life Sciences Ltd. today announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.

15 Jul 2010

BARRX Medical closes $15 million Series D financing

BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.

14 Jul 2010

Samsung Medical Center, Pfizer form research partnership

Samsung Medical Center and the world's leading bio-pharmaceutical company Pfizer Inc. announced that they have formed a research partnership to jointly analyze tumors from Korean patients to generate gene expression profiles and that may ultimately direct therapies and enhance clinical outcomes in the patients with liver cancer.

14 Jul 2010

Trevena completes $35M Series B financing

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor biased ligands, announced today that it has completed a $35 million Series B financing. Existing investors Polaris Venture Partners and New Enterprise Associates led the round, with all other existing Trevena investors - Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company - also participating in the financing.

14 Jul 2010

SANUWAVE Health introduces orthoPACE device in Europe

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reports the European launch of the orthoPACE device intended for use in orthopedic, trauma and sports medicine indications following CE mark approval last month.

14 Jul 2010

ZYTO announces launch of redesigned corporate website

ZYTO Corp, www.ZYTO.com, is pleased to announce the launch of its completely redesigned corporate website. The updated site is the result of extensive analysis, design, and programming.

14 Jul 2010

Pacific Biosciences completes $109M Series F financing round

Pacific Biosciences, a private company developing a disruptive technology platform for real-time detection of biological events at single molecule resolution, today announced it has completed a Series F round of financing in the amount of $109 million.

14 Jul 2010